{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"40.60","value":"22.36"},{"groupId":"OG001","spread":"28.62","value":"19.87"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"122"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Serum CRP on Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"47.35","value":"29.30"},{"groupId":"OG001","spread":"42.50","value":"32.94"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Serum CRP on Day 0"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"91.76","value":"72.50"},{"groupId":"OG001","spread":"92.82","value":"66.73"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"},{"groupId":"OG001","value":"27"}],"units":"Participants"}],"title":"Serum CRP on Day 3"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"79.24","value":"59.45"},{"groupId":"OG001","spread":"91.86","value":"77.79"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Serum CRP on Day 7"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"19.70","value":"9.07"},{"groupId":"OG001","spread":"42.20","value":"13.59"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"113"},{"groupId":"OG001","value":"26"}],"units":"Participants"}],"title":"Serum CRP on Week 2"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"33.76","value":"7.84"},{"groupId":"OG001","spread":"43.46","value":"9.86"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"118"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"title":"Serum CRP on Week 4"}],"denoms":[{"counts":[{"groupId":"OG000","value":"123"},{"groupId":"OG001","value":"28"}],"units":"Participants"}],"dispersionType":"Standard Deviation","groups":[{"description":"Participants with r/r B-cell iNHL subtype of FL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG000","title":"Axicabtagene Ciloleucel (Follicular Lymphoma)"},{"description":"Participants with r/r B-cell iNHL subtype of MZL received the following treatment during the study:\n\n* A conditioning chemotherapy regimen of fludarabine 30 mg/m\\^2/day IV and cyclophosphamide 500 mg/m\\^2/day IV for 3 days (Day -5 to Day -3).\n* A single IV infusion at a target dose of 2×10\\^6 anti-CD19 CAR transduced autologous T cells/kg on Day 0.","id":"OG001","title":"Axicabtagene Ciloleucel (Marginal Zone Lymphoma)"}],"paramType":"MEAN","populationDescription":"Participants in the Safety Analysis Set with available data were analyzed.","reportingStatus":"POSTED","timeFrame":"Baseline (at enrollment), predose: Day 0, postdose: Day 3, Day 7, Week 2, Week 4","title":"Levels of Serum C-Reactive Protein (CRP)","type":"SECONDARY","unitOfMeasure":"mg/L"}